Calling Bioatla LLC's Conditionally Active Biologics (CAB) platform "the key piece for getting [an antibody-drug conjugate (ADC)] where it needs to go," CEO Jay Short told BioWorld Today the new deal with Pfizer Inc. represents "the marrying of two world-class technologies." Read More
The pick-up of Synageva Biopharma Corp. provided an early payback for Alexion Pharmaceuticals Inc., which saw the FDA green-light Kanuma (sebelipase alfa) as the first approved U.S. therapy to treat patients with lysosomal acid lipase deficiency. Read More
DUBLIN – Pieris Pharmaceuticals Inc., logged its first partnering deal in immuno-oncology, a pact worth up to CHF415 million (US$416 million) with Roche AG, involving a single undisclosed target against which the German-American biotech will deploy its anticalin scaffold technology. Read More
HONG KONG – Three-year old Chinese novel monoclonal antibody (MAb) developer Akeso Biopharma Inc. has signed a $200 million deal with MSD China, out-licensing its first compound. The deal comes on the heels of closing a $20 million series A financing funded by local investors. Read More
ORLANDO, Fla. – Precision medicine has replaced personalized medicine as the catchphrase of the day, with the change often being explained on the grounds that medicine has always been personalized. Read More
NEW DELHI – Indian generics drugmaker Cipla Ltd. said it will explore all legal options available after an Indian court's recent ruling that the firm infringed the patent rights of Swiss drug major Roche AG regarding lung cancer drug erlotinib. Read More
SHANGHAI – Getting a drug to patients in China's huge, fractured market is no easy task. But it is a challenge China's state-owned firm, Sinopharm Group, happens to have well under control: It is China's biggest drug distributor, and, not surprisingly, it is the first firm in China's health care sector to make the Fortune 500 list. Last year, Sinopharm's revenues topped $30 billion. Read More
Tiziana Life Sciences plc, of London, said it raised about £3.8 million (US$5.7 million) through the issue of about 2.6 million unsecured convertible loan notes to investors. Read More
Sunesis Pharmaceuticals Inc., of South San Francisco, submitted a marketing authorization application with the EMA for vosaroxin to treat acute myeloid leukemia (AML) in patients, ages 60 and older. Read More
